The FDA on Feb. 10 expanded Pfizer’s Cibinqo’s approved use in atopic dermatitis. Its use now includes patients age 12 to 18 with “with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable,” according to a Pfizer press release. For the treatment of atopic dermatitis, the JAK inhibitor currently holds covered or better status for 78% of all insured lives under the pharmacy benefit. About 22% of covered lives have preferred access to Cibinqo, largely with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 2/15/23